Tenderwize
Wróć do wyszukiwania

Open-house pharmaceutical discount agreements for Atovaquone

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Mar 03, 2028 · 553 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Atovaquon, ATC P01AX06

58/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

58 / 100

Złożoność

45 / 100

Czynniki ryzyka

The notice uses an open procedure form, but both structured data and XML state the substance is an open-house model out...

Timing is strict: to start on the next month’s first day, complete documents must arrive by the 3rd of the month; for p...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Non-exclusive pharmaceutical discount agreement for Atovaquone (ATC P01AX06).
  • Open-house accession model with identical, pre-defined contractual terms for all eligible companies.
Pokaż pełne podsumowanie

This is an open-house supply arrangement for pharmaceutical discount agreements on Atovaquone (ATC P01AX06) by AOK Bayern. It is not a competitive award procedure in substance, but an accession model with identical non-negotiable terms for all eligible pharmaceutical companies. Contracting is possible until 03.03.2028, with possible start dates on the first day of the following month if complete documents are received by the 3rd, or the month after if later. No contract value is stated.

Ryzyka

The notice uses an open procedure form, but both structured data and XML state the substance is an open-house model out...

Timing is strict: to start on the next month’s first day, complete documents must arrive by the 3rd of the month; for p...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • The contract and the annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be completed and signed.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open-house pharmaceutical discount agreements for Atovaquone

Single lot covering non-exclusive open-house Rabattverträge for the active substance Atovaquone (ATC P01AX06). The lot is for supply-type pharmaceutical products in Germany (Bavaria/Munich contracting authority). Terms are fixed and non-individually negotiable.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Apr 2026 - Apr 2028

Kategoria

Pharmaceutical products

Termin

Deadline Mar 03, 2028

Szczegóły zamówienia

Data publikacji
15 Mar 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
179704-2026

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30